Drug Development's Marathon Endurance Race: The CMO's Leadership in Patient-Centric Innovation
2025/03/31
再生時間： 23 分
ポッドキャスト

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

Drug Development's Marathon Endurance Race: The CMO's Leadership in Patient-Centric Innovation

無料で聴く

ポッドキャストの詳細を見る

サマリー
In this episode of PEP Talks, Emma interviews Dr. David Gillen, the Chief Medical Officer of Norgine, discussing the evolution and importance of patient engagement in the pharmaceutical industry. Reflecting on their first meeting 16 years ago, they explore how patient demands and advocacy have shaped industry practices.
Dr. Gillen emphasises the critical role of patient engagement professionals in drug development, highlighting the shift from a physician-centric approach to a more patient-focused strategy. He acknowledges the challenges and benefits of integrating patient voices into clinical trials, regulatory frameworks, and medical affairs. The conversation also touches on the impact of social media and online communities in amplifying patient voices, the professionalisation of patient engagement, and the complexities of developing medicines for paediatric populations.
Dr. Gillen shares insights on balancing safety, efficacy, and patient needs, and underscores the importance of teamwork and resilience in overcoming obstacles in medicine development.

続きを読む一部表示

あらすじ・解説

In this episode of PEP Talks, Emma interviews Dr. David Gillen, the Chief Medical Officer of Norgine, discussing the evolution and importance of patient engagement in the pharmaceutical industry. Reflecting on their first meeting 16 years ago, they explore how patient demands and advocacy have shaped industry practices.

Dr. Gillen emphasises the critical role of patient engagement professionals in drug development, highlighting the shift from a physician-centric approach to a more patient-focused strategy. He acknowledges the challenges and benefits of integrating patient voices into clinical trials, regulatory frameworks, and medical affairs. The conversation also touches on the impact of social media and online communities in amplifying patient voices, the professionalisation of patient engagement, and the complexities of developing medicines for paediatric populations.

Dr. Gillen shares insights on balancing safety, efficacy, and patient needs, and underscores the importance of teamwork and resilience in overcoming obstacles in medicine development.

続きを読む一部表示